Hemophilia and Thrombosis Center, Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado-Anschutz Medical Campus, 13123 East 16th Avenue, Aurora, CO 80045, USA.
Department of Pathology and Laboratory Medicine, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA; Department of Pathology, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
Clin Lab Med. 2021 Mar;41(1):121-132. doi: 10.1016/j.cll.2020.10.008.
Advances in cellular therapies for pediatric patients have created many opportunities for improved survival with reduced morbidity. This article reviews current cellular therapies in pediatric hematological malignancy, including the most updated practices in hematopoietic stem cell transplant and the use of chimeric antigen receptor (CAR) therapy in T cells. Hematopoietic stem cell transplant has evolved with improvements in chemotherapy regimens, immunosuppression, and donor-matching options. Novel therapies in development which will likely further improve the options for patients are reviewed including Natural Killer, Regulatory T-cells and αβ depletion.
细胞疗法在儿科患者中的进展为提高生存率和降低发病率创造了许多机会。本文综述了儿科血液恶性肿瘤的细胞疗法，包括造血干细胞移植的最新实践和嵌合抗原受体（CAR）疗法在 T 细胞中的应用。造血干细胞移植随着化疗方案、免疫抑制和供者匹配选择的改进而不断发展。本文还回顾了正在开发的可能进一步改善患者治疗选择的新型疗法，包括自然杀伤细胞、调节性 T 细胞和 αβ 细胞耗竭。
